Gilead Sciences
-
{
- All
- News
- Videos
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
How an $84,000 Drug Got Its Price: 'Let's Hold our Position... Whatever the Headlines'
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
US Regulator Approves Gilead Sciences' HIV Drug Cocktail
Gilead Sciences Inc said the US Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above.
-
US Regulator Approves Gilead Sciences' HIV Drug Cocktail
Gilead Sciences Inc said the US Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
How an $84,000 Drug Got Its Price: 'Let's Hold our Position... Whatever the Headlines'
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
US Regulator Approves Gilead Sciences' HIV Drug Cocktail
Gilead Sciences Inc said the US Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above.
-
US Regulator Approves Gilead Sciences' HIV Drug Cocktail
Gilead Sciences Inc said the US Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above.
